Last reviewed · How we verify
NCT07117461
A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer
NA trial testing NCCN Distress Thermometer in Solid Tumor Cancer in 50 participants. Currently enrolling.
22 July 2026
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 50 |
| Start date | 22 July 2025 |
| Primary completion | 22 July 2026 |
| Estimated completion | 22 July 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- NCCN Distress Thermometer
Conditions studied
- Solid Tumor Cancer — all drugs for Solid Tumor Cancer →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Solid Tumor Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is recommended that cancer centers screen patients for distress and refer them to mental health services when their distress levels reach a certain level. However, many cancer centers don't have distress screening and referral programs. This study will provide valuable information about one distress screening and referral program and whether it can be helpful for a large and diverse group of cancer patients that includes both English- and Spanish-speaking patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07117461
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor Cancer
Currently open trials in the same condition.
- NCT06802172 — Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial · NA · recruiting
- NCT07441174 — IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Soli · Phase 1, PHASE2 · recruiting
- NCT07218874 — Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application · NA · recruiting
- NCT07269899 — A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07146672 — Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors · Phase 1, PHASE2 · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07117461 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 16 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07117461.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing